Kin-Ming Lo

"One for the Patients" drives my motivation and innovative molecules improve patients' lives.

Perspective

"One for the Patients" drives my motivation and innovative molecules such as M7824 may improve patients' lives. I hope to continue making contributions to the EMD Serono pipeline by proposing and designing differentiated therapeutic concepts for validated targets.

"One for the Patients" drives my motivation and innovative molecules such as M7824 may improve patients' lives.

Kin-Ming Lo

Executive Scientific Director, Head of NBE Concept Validation, TIP Immuno-Oncology

Profile

Joined Merck KGaA, Darmstadt, Germany: 1992

Key research fields and topics:

  • Redirecting immunotherapy to the tumor microenvironment using antibody cytokine traps, immunocytokines, T cell engagers, and other bifunctional fusion proteins

Prizes and awards:

  • EMD Serono Achievement Award, 2009
  • Merck KGaA, Darmstadt, Germany Science Award, 2019
  • Co-recipient of the Merck KGaA, Darmstadt, Germany Technology Award, 2019
  • Co-recipient of the Merck KGaA, Darmstadt, Germany Preclinical Publication Prize, 2019

CV & Scientific activities

CV: Education

CV: Education

1975
B.A., Chemistry (cum laude) and Asian Studies (cum laude), Cornell University
1978
M.S., Chemistry, Cornell University
1981
Ph.D., Bioorganic Chemistry, Cornell University
1981 - 1984
Postdoctoral Research Associate with H. Gobind Khorana, Massachusetts Institute of Technology

CV: Professional Career

CV: Professional Career

1984 - 1986
Senior Research Scientist, Damon Biotech, Inc., Needham, MA
1986 - 1988
Principal Research Scientist
1988 - 1990
Director of Molecular Biology
1990 - 1992
Head of Molecular Biology, Abbott Biotech, Inc., Needham, MA
Mar - Jul - 1992
Visiting Scientist, Dana Farber Cancer Institute, Boston, MA
1992 - 1995
Director of Molecular Biology, Fuji ImmunoPharmaceuticals, Lexington, MA
1995 - 1997
Senior Director of Molecular Biology
1997 - 1998
Vice President of Molecular Biology, Shionogi BioResearch, Lexington, MA
1998 - 2007
Vice President of Research, EMD Lexigen Research Center, Billerica, MA (formerly Lexigen Pharmaceuticals Corp.,Lexington, MA)
2007 - 2008
Global Head of Antibody Technologies, EMD Serono Research Institute, Billerica, MA
2008 - 2009
Head of Protein Engineering and Antibody Technologies, US
2009 - 2012
Director of Protein Engineering and Antibody Technologies Innovation
2012 - 2014
Director of ImmunoTechnologies, ImmunoOncology Translational Innovation Platform, Global Research and Early Development, EMD Serono Research and Development Institute, Billerica, MA
2014 - 2015
Senior Director of ImmunoTechnologies
2015 - 2017
Senior Director of Redirected Immunoregulation
since 2017
Executive Scientific Director of Redirected Immunotherapy

References

Publications
 
  • Schultz, A.G., Fu W.Y., Lucci, R.D., Kurr, B.G., Lo, K.-M., and Boxer, M.   Heteroatom Directed Photoarylation.  Synthetic Potential of the Heteroatom Sulphur.  J. Am. Chem. Soc. 100:2140-49, 1978.
  • Profy, A.T., Lo, K.-M., and Usher, D.A.   Synthesis of 2'(3')-O-DL-alanyl hexainosinic acid using T4 RNA ligase: suppression of the enzymic reverse transfer reaction by alkaline phosphatase.  Nucleic Acids Res. 11(5):1617-32, 1983.
  • Usher, D.A., Profy, A.T., Walstrum, S.A., Needels, M.C., Bulack, S.C., and Lo, K.-M.   Nucleic acids, proteins, and chirality.  Orig Life 14:621-8, 1984.
  • Dunn, R.J., Hackett, N.R., Huang, K.-S., Jones, S.S., Lee, D.-S., Liao, M.-J., Lo, K.-M., McCoy, J.M., Noguchi, S., Radhakrishnan, R., RajBhandary, U.L., and Khorana, H.G.   Studies on the Light -Transducing Pigment, Bacteriorhodopsin and Rhodopsin.   Cold Spring Harbor Symposia on Quantitative Biology 48: 853-862, 1983.
  • Lo, K.-M., Jones, S.S., Hackett, N.R., and Khorana, H.G.   Specific Amino Acid Substitutions in Bacterio-opsin: I. Replacement of a Restriction Fragment in the Structural Gene by Synthetic DNA Fragments Containing Altered Codons.   Proc. Natl. Acad. Sci. USA, 81: 2285-2289, 1984.
  • Chipperfield, R.G., Jones, S.S., Lo, K.-M., and Weinberg, R.A.    Activation of Ha-ras p21 by Substitution, Deletion and Insertion Mutations.   Molec. Cellular Biol. 5: 1809-1813, 1985.
  • Gilles-Gonzalez, M.A., Hackett, N.R., Jones, S.S., Khorana, H.G., Lee, D.-S., Lo, K.-M., and McCoy, J.M.   Methods for Mutagenesis of the Bacterioopsin Gene.  Methods Enzymol. 125: 190-215, 1985.
  • Khorana, H.G., Braiman, M.S., Chao, B.H., Doi, T., Flitsch, S.L., Gilles-Gonzalez, M.A., Hackett, N.R., Jones, S.S., Karnik, S.S., Lo, K.-M., Marti, T., Mogi, T., Nassal, M.M., Stern, L.J., and Subramaniam, S.   Studies on Bacteriorhodopsin II.   Structure and Expression, Vol. 1: From Proteins to Ribosomes eds. Sarma, R.H. and Sarma, M.H. (Adenine Press) pp.1-23, 1988.
  • Gillies, S.D., Lo, K.-M., and Wesolowski, J.   High-level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes.   J.  Immunol.  Methods.  125: 191-202, 1989.
  • Lo, K.-M., and Gillies, S.D.   High-level Expression of Human Proteins in Murine Hybridoma Cells:  Induction by Methotrexate in the Absence of Gene Amplification.  Biochimica et Biophysica Acta, 1088: 217-224, 1991.
  • Gillies, S.D., Young, D., Lo, K.-M., Foley, S.F., and Reisfeld, R.A.   Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-ganglioside GD2 Antibody.   Hybridoma 10: 347-356, 1991.
  • Gillies, S.D., Wesolowski, J.S., and Lo, K.-M.   Targeting Human Cytotoxic T Lymphocytes to Kill Heterologous Epidermal growth Factor Receptor-Bearing Tumor Cells.   J. Immunol.  146: 1067-1071, 1991.
  • Gillies, S.D., Reilly, E.B., Lo, K.-M., and Reisfeld, R.A.  Antibody-targeted IL-2 Stimulates the Killing of Autologous Tumor Cells.   Proc.  Natl.  Acad.  Sci.  USA 89:1428-1432, 1992.         
  • Lo, K.-M., Lynch, C.A., and Gillies, S.D.   The Use of Wild-type Dihydrofolate Reductase-encoding cDNA as a Dominant Selectable Marker and Induction of Expression by Methotrexate.   Gene 121: 365-369, 1992.  
  • Lo, K.-M., Roy, A., Foley, S.F., Coll, J.T., and Gillies, S.D.   Expression and Secretion of an Assembled Tetrameric CH2-Deleted Antibody in E. coli.   Hum. Antibodies Hybridoma 3: 123-128, 1992.
  • Gillies, S.D., Young, D., Lo, K.-M., and Roberts, S.   Biological Activity and in vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins.   Bioconjugate Chemistry 4:  230-235, 1993.
  • Ono, M., Wada, Y., Wu. Y.,Nemori, R., Jinbo, Y., Wang, H., Lo, K.-M., Yamaguchi, N., Brunkhorst, B., Otomo, H., Wesolowski, J., Way, J.C., Itoh, I., Gillies, S., and Chen, L.B.   FP21399 Blocks HIV Envelope Protein-Mediated Membrane Fusion and Concentrates in Lymph Nodes.  Nature Biotechnology 15:343-348, 1997.
  • Xiang, R., Lode, H.N., Dolman, C.S., Dreier, T., Varki, N.M., Qian, X., Lo, K.-M., Lan, Y., Super, M., Gillies, S.D., and Reisfeld, R.A.   Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy.  Cancer Res.  57:4948-4955, 1997.
  • Lo, K.-M., Sudo, Y., Chen, J., Li, Y., Lan, Y., Kong, S.-M., Chen, L., An, Q., and Gillies, S.G.   High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells.   Protein Engineering 11:495-500, 1998.
  • Gillies, S.D., Lan, Y., Wesolowski, J.S., Qian, X., Reisfeld, R.A., Holden, S., Super, M., and Lo, K.-M.   Antibody-IL-12 Fusion Proteins Are Effective in SCID Mouse Models of Prostate and Colon Carcinoma Metastases.  J. Immunol. 160:6195-6203, 1998.
  • Ding, Y.-H., Javaherian, K., Lo, K.-M., Chopra, R., Boehm, T., Lanciotti, J., Harris, B.A., Li, Y., Shapiro, R., Hohenester, E., Timpl, R., Folkman, J., and Wiley, D.   Zinc-dependent Dimers Observed in Crystals of Human Endostatin.  Proc. Natl. Acad. Sci. USA 95:10443-10448, 1998.
  • Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., and Hanahan, D.   Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice.  Science 284:808-812, 1999.
  • Bao, S., Chang, M.S., Auclair, D., Sun, Y., Wang, Y., Wong, W.K., Zhang, J., Liu, Y., Qian, X., Sutherland, R., Magi-Galluzi, C., Weisberg, E., Cheng, E.Y. Hao, L., Sasaki, H., Campbell, M.S., Kraeft, S.K., Loda, M., Lo, K.M., and Chen, L.B.   Hrad17, a human homologue of the Schizosaccharomyces pombe checkpoint gene rad17, is overexpressed in colon carcinoma. Cancer Res.  59:2023-2028, 1999.
  • Gillies, S.D., Lan, Y., Lo, K.-M., Super, M., and Wesolowski, J.S.   Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing their Interaction with Fc Receptors. Cancer Res.  59:2159-2166, 1999.
  • Beecken, W.C., Fernandez, A., Joussen, A.M., Achilles, E., Flynn, E., Lo, K.-M., Gillies, S.D., Javaherian, K., Folkman, J., and Shing, Y.   Effect of Antiangiogenic Therapy on Slowly Growing, Poorly Vascularized Tumors in Mice.  J. Natl. Cancer Institute 93:382-387, 2001. 
  • Kuo, C.J., LaMontagne, Jr, K.R., Garcia-Cardena, G., Ackley, B.D., Kalman, D., Christofferson, R., Kamihara, J., Ding, Y.-H., Lo, K.-M., Gillies, S.D., Folkman, J., Mulligan, R.C., and Javaherian, K.  Oligomerization-Dependent Regulation of Cellular Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain.   J. Cell Biol. 152:1233-1246, 2001.
  • Sasaki, H., Lo, K.-M., Chen, L.B., Auclair, D., Nakashima, Y., Moriyama, S., Fukai, I., Tam, C., Loda, M., Fujii, Y.   Expression of Periostin, Homologous with an Insect Cell Adhesion Molecule, as a Prognostic Marker in Non-Small Cell Lung Cancers.  Jpn J Cancer Res. 92:869-873, 2001.
  • Gillies, S.D., Lo, K.-M., Burger, C., Lan, Y., Dahl, T., and Wong, W.-K.   Improved Circulating Half-life and Efficacy of an Antibody-Interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis.  Clinical Cancer Research 8:210-216, 2002.
  • Gillies, S.D., Lan, Y., Brunkhorst, B., Wong, W.-K., Li, Y., and Lo, K.-M.   Bi-functional Cytokine Fusion Proteins for Gene Therapy and Antibody-targeted Treatment of Cancer.  Cancer Immunol. Immunother. 51:449-460, 2002.
  • Javaherian, K., Park, S.Y., Winfried F.P., LaMontagne, K.R., Sjin, R.T.T., Gillies, S.D., and Lo, K.-M. Laminin Modulates Morphogenic Properties of the Collagen XVIII Endostatin Domain.  J. Biol. Chem. 277:45211-45218, 2002.
  • Moulton, K.S., Vakili, K., Zurakowski, D., Soliman, M., Butterfield, C., Sylvin, E., Lo, K.-M., Gillies, S.D., Javaherian, K., and Folkman, J.   Inhibition of Plaque Neovascularization Reduces Macrophage Accumulation and Progression of Advanced Atherosclerosis.  Proc.  Natl.  Acad.  Sci. USA 100:4736-4741, 2003.
  • Korokhov N., Mikheeva G., Krendelshchikov A., Belousova N., Simonenko V., Krendelshchikova V., Pereboev A., Kotov A., Kotova O., Triozzi P.L., Aldrich W.A., Douglas J.T., Lo K.-M., Banerjee P.T., Gillies S.D., Curiel D.T., and Krasnykh V.  Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge.  J. Virol. 77:12931-40, 2003.
  • Mhaka, A., Gady, A.M., Rosen, D. M., Lo, K.-M., Gillies, S.D., and Denmeade, S.R.   Use of Methotrexate-Based Peptide Substrates to Characterize the Substrate Specificity of Prostate-Specific Membrane Antigen (PSMA) Cancer Biology and Therapy 3: 551-558, 2004.
  • Jones, T.D., Hanlon, M., Smith, B.J., Heise, C.T., Nayee, P.D., Sanders, D.A., Hamilton, A., Sweet, C., Unitt, E., Alexander, G., Lo, K.-M., Gillies, S.D, Carr, F.J., and Baker, M.P.   The development of a modified human interferon-2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C infection.  J Interferon and Cytokine Res. 24:560-572, 2004.
  • Gillies, S.D., Lan, Y., Williams, S., Carr, F., Raubitschek, A., and Lo, K.-M.   An anti-CD20-IL2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 105:3972-3978, 2005.
  • Lo, K.-M., Zhang, J., Sun, Y., Morelli, B., Lan, Y., Lauder, S., Brunkhorst, B., Webster, G., Hallakou-Bozec, S., Doaré, L., and Gillies, S.D.   Engineering a pharmacologically superior form of leptin for the treatment of obesity.  Protein Engineering Design and Selection, 18:1-10, 2005.
  • Way, J.C., Lauder, S., Brunkhorst, B., Kong, S.-M., Qi, A., Webster, G., Campbell, I., McKenzie, S., Yan Lan, Y., Marelli, B., Lo, K.-M., and Gillies, S.D.   Enhancement of Fc-erythropoietin pharmacokinetics through modification of disulfide bonds.  Protein Engineering Design and Selection, 18:111-118, 2005.
  • Tjin, R.M., Napinski, J., Birsner, A.E., Li, C., Chan, R., Lo, K.-M., Gillies, S.D., Zurakowski D., Folkman, J., Samulski, J., and Javaherian, K.   Endostatin Therapy Reveals a U-shaped Curve for Antitumor Activity.  Cancer Gene Therapy, 13:619-27, 2006. 
  • Lo, K.-M., Lan, Y., Lauder, S., Zhang, J., Brunkhorst, B., Qin, G.,  Verma, R., Courtenay-Luck, N., and Gillies, S.D.  huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models.  Cancer Immunology Immunotherapy, 56:447-457, 2007.
  • Lee, T.-Y., Tjin, R.M., Sjin, T., Movahedi, S., Ahmed, B., Pravda, E.A., Lo, K.-M., Gillies, S.D., Folkman, J., and Javaherian, K.   Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy.  Clin. Cancer Res. 14:1487-1493, 2008.
  • Hank, J. A., Gan, J., Ryu, H., Ostendorf, A., Stauder, M. C., Sternberg, A., Albertini, M., Lo, K.-M., Gillies, S.D., Eickhoff, J., Sondel, P.M.  Immunogenicity of the Hu14.18-IL2 Immunocytokine Molecule in Adults with Melanoma and Children with Neuroblastoma. Clin. Cancer Res. 15:5923-30, 2009.
  • Davis, J.H., Aperlo, C., Li, Y., Kurosawa, E., Lan, Y., Lo, K.-M., and Huston, J.S. SEEDbodies: Fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Engineering Design and Selection, 13:195-202, 2010.
  • Gillies, S.D., Lan, Y., Hettmann, T., Brunkhorst, B., Sun, Y., Mueller S.O., and Lo, K.-M.  A low-toxicity IL-2 based immunocytokine retains anti-tumor activity despite its high degree of IL-2 receptor selectivity.  Clin. Cancer Res. 17:3673-85, 2011.
  • Lo, K.-M., Leger, O., and Hock, B. Chapter 38 Antibody Engineering in Antibody for Infectious Disease. James E. Crowe, Jr., Diana Boraschi, and Rino Rappuoli, Editors, ASM Press, 2015. 
  • Waight, J.D., Takai, S., Marelli, B., Guozhong, Q., Hance, K.W., Zhang, D., Tighe, R., Lan, Y., Lo, K.-M., Sabzevari, H., Hofmeister, R., and Wilson, N.S. Epigenetic regulation of FoxP3 defines a homogenous population of stable CD4+ regulatory T cells in tumors from mice and humans.  J. Immunol. 194:878-882, 2015.
  • Xu C., Zhang Y., Rolfe P.A., Hernández V.M., Guzman W., Kradjian G., Marelli B., Qin G., Qi J., Wang H., Yu H., Tighe R., Lo K.-M., English J.M., Radvanyi L.G., Lan Y. Combination therapy with NHS-muIL12 and avelumab (anti-PD-L1) enhances antitumor efficacy in preclinical cancer models.Clin Cancer Res. 23:5869-5880, 2017.
  • Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, Yu H, Qin G, Sircar A, Hernández VM, Jenkins MH, Fontana RE, Deshpande A, Locke G, Sabzevari H, Radvanyi L, and Lo K-M. Enhanced pre-clinical anti-tumor activity of M7824, a novel bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Science Translational Medicine Vol 10, Issue 424, eaan5488, Jan 17, 2018.

Patents and Patent Applications         

  • Ono, M., Wada, Y., Wu, Y., Kitaguchi, H., Jimbo, Y., Nemori, R., Gillies, S.D., and Lo, K.-M. (1994). Method for Inhibiting Retroviral Infection by Administering a Naphthalenesulfonic Acid Compound.  US Patent 5,589,510, issued December 31, 1996.
  • Lo, K.-M., Sudo, Y., and Gillies, S.D. (1995).  Expression and Export Technology of Proteins as Immunofusins.  US Patent 5,541,087, issued July 30, 1996; EP 0782625 B1, granted May 9, 2007.
  • Lo, K.-M., and Gillies, S.D. (1995).  Expression Induction Method.  US Patent 5,741,682, issued April 21, 1998.
  • Gillies, S.D., Lan, Y., and Lo, K.-M. (1997). Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation.  US Patent 6,838,260, issued Jan 04, 2005.
  • Lo, K.-M., Sudo, Y., and Gillies, S.D. (1998).  Expression and Export Technology of Proteins as Immunofusins, Continuation-in-part.  US Patent 5,726,044, issued March 10, 1998.
  • Lo, K.-M., Li, Y., and Gillies, S.D. (1998).  Expression and Export of Angiogenesis Inhibitors as Immunofusins.  US20030139365 A1.  Patent Status: Pending.
  • Lo, K.-M., Zhang, J., and Gillies, S.D. (1998).  Expression and Export of Anti-Obesity Proteins as Fc Fusion Proteins.  US20040053366 A1.  Patent Status: Pending.
  • Lo, K.-M., Li, Y., and Gillies, S.D.  Expression and Export of Angiostatin and Endostatin as Immunofusins.  EP1107989B1 issued Mar 31, 2010.
  • Lo, K.-M., Li, Y., and Gillies, S.D.  Expression and Export of Angiogenesis Inhibitors as Immunofusins.  US Patent 8703908, issued April 22, 2014.
  • Gillies, S.D., Lo, K.-M., Lan, Y., and Wesolowski, J. (1999).  Enhancing the Circulating Half-Life of Antibody-based Fusion Proteins.  US20030105294 A1.  Patent Status: Pending.
  • Gillies, S.D., and Lo, K.-M. (2000). Multiple cytokine protein complexes.  US Patent 6,617,135, issued Sept 9, 2003.
  • Gillies, S.D., Lo, K.-M., and Wesolowski, J. S. (2000).  Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens.  US Patent 7,067,110, issued June 27, 2006; EP 1198250 B1 granted Sept 26, 2007.
  • Lo, K.-M., Sun, Y., and Gillies, S.D. (2000).  Expression and Export of Interferon-Alpha Proteins as Fc Fusion Proteins.  US20050042729 A1. International application number PCT/US2000/013827.
  • Gillies, S.D., Burger, C., and Lo, K.-M. (2001). Enhancing the Circulating Half-Life of Antibody-based Fusion Proteins.  US Patent 7,091,321, issued Aug 15, 2006; EP1489100B1 granted June 15, 2016.
  • Gillies, S.D., Burger, C., and Lo, K.-M. (2001). Enhancing the Circulating Half-Life of Antibody-based Fusion Proteins.  US Patent 7,790,415, issued Sept 7, 2010.
  • Gillies, S.D., Lo, K.-M., and Lan, Y. (2001).  Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation.  US Patent 7,226,998, issued June 5, 2007.
  • Gillies, S.D., Lo, K.-M., and Lan, Y. (2001).  Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation.  US Patent 7,879,319, issued Feb 1, 2011.
  • Gillies, S.D., Lo, K.-M., and Qian, S.X. (2002).  Recombinant tumor specific antibody and uses thereof.  US Patent 6,969,517, issued Nov 29, 2005.
  • Gillies, S.D., Stein, P.A., and Lo, K.-M. (2002). IL-2 fusion proteins with modulated selectivity.  US Patent 7,186,804, issued March 6, 2007. 
  • Gillies, S.D., Stein, P.A., and Lo, K.-M. (2006). Cancer treatments including administering IL-2 fusion proteins with modulated selectivity.  US Patent 7,462,350 B2, issued Dec 9, 2008.
  • Gillies, S.D., Stein, P.A., and Lo, K.-M. (2008). DNA encoding IL-2 fusion proteins with modulated selectivity.  US Patent 7,888,071 B2, issued Feb 15, 2011.
  • Gillies, S.D., and Lo, K.-M. (2002). Expression technology for proteins containing a hybrid isotype antibody moiety.  US Patent 7,148,321, issued Dec 12, 2006.
  • Gillies, S.D., and Lo, K.-M. (2003). Multiple cytokine protein complexes.  US Patent 7,141,651, issued Nov 28, 2006.
  • Gillies, S.D., and Lo, K.-M., (2002) Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2. EP1 572 748 B1 issued June 23, 2010.
  • Gillies, S.D., Lo, K.-M., and Qian, S.X. (2003).  Immunocytokine sequences and uses thereof.  US Patent 7,169,904, issued Jan 30, 2007.
  • Gillies, S.D., Lo, K.-M., and Qian, S.X. (2002).  Recombinant tumor specific antibody and uses thereof.  US Patent 7,459,538, issued Dec 2, 2008. EP 1 383 785 B1 issued March 16, 2011.
  • Gillies, S.D., Lo, K.-M., and Qian, S.X. (2003).  Immunocytokine sequences and uses thereof.  US Patent 7,767,405, issued Aug 03, 2010.
  • Gillies S.D., Lo, K.-M., and Way, J.C.  (2005)  Fc-erythropoietin fusion protein with improved pharmacokinetics.  US20050202538 A1. Patent Status: Pending.
  • Gillies, S.D., Watkins, N.J., Baker, M.P., Lo, K.-M., and Degon, S.C. (2005) Stabilization of Fc-interferon-beta fusion proteins. US 8,557,232, issued Oct 15, 2013.
  • Gillies, S.D., Watkins, N.J., Baker, M.P., and Lo, K.-M. (2005)  Fc-interferon-beta fusion proteins. EP1761559B1 issued Sept. 23, 2009.
  • Gillies, S.D., Stein, P.A., and Lo, K.-M. (2006)  Cancer treatments including administering IL-2 fusion proteins with modulated selectivity.  US Patent 7,462,350, issued Dec 9, 2008.
  • Gillies, S.D., Stein, P.A., and Lo, K.-M. (2006)  DNA encoding IL-2 fusion proteins with modulated selectivity.  US Patent 7,888,071, issued Feb 25, 2011.
  • Way, J.C., Gillies S.D., Lo, K.-M., and Liu, Y. (2006).  Interleukin-6 antagonists. US20070178098 A1.  Patent Status: Pending.
  • Webster, G.D., McKenzie, S.P., Lo, K.-M., and Stein, P.A. (2006).  Interleukin-12p40 variants with improved stability. US Patent 7,872,107, issued Jan 18, 2011.
  • Gillies, S.D., Lo, K.-M., Lan, Y., and Verma, R. (2005) Compounds for Targeting.  US20070202103 A1. Patent Status: Pending.
  • Gillies, S.D., Lo, K.-M., Lan, Y., and Wesolowski, J. (2006) Enhancing the Circulating Half-Life of Antibody-based Fusion Proteins.  US20060194952 A1.  Patent Status: Pending.
  • Gillies, S.D., Lo, K.-M., and Lan, Y. (2007) Methods for enhancing the efficacy of IL-2 mediated immune responses. US20080025947 A1 Patent Status: Pending.
  • Goodman, S., Hahn, D., Mitjans, F., and Lo, K.-M, (2007) Engineered anti-alpha v integrin hybrid antibodies. US 8,562,986, issued Oct 22, 2013. WO 2009/010290, pending.
  • Lo, K.-M., and Stein, P.A. (2010).  Antibody Fusion Proteins with a Modified FcRn Binding Site. US 8,907,066, issued Dec 9, 2014.
  • Lo, K.-M., and Zizlsperger, N.  Tetravalent Bispecific Antibodies. US/15.03.13/ US201361793153. Patent Status: Pending.
  • Lo, K.-M. Targeted TGF inhibition. US Patent 9,676,863 B2, issued June 13, 2017.  US 20150225483 A1 and WO 2015118175 A2 pending.
  • Lo, K.-M., Zizlsperger, N., and Aroop, S. (Provisional filed Aug 15, 2014).  SIRP immunoglobulin fusion proteins. Patent Status: Pending.
  • Lo, K.-M., and Lan, Y. (Utility filed 8/21/2017) Combination Therapy for Cancer 
  • Lo, K.-M., and Lan, Y. (2017) Combination Therapy for Cancer, WO-2018029367-A1. Patent Status: Pending

Oral and  Poster Presentations on M7824

  • Lo, KM. Oral presentation on Anti-PD-L1/TGF Trap, CIMT Annual Meeting, Mainz, Germany, May 12, 2016.
  • Lan Y, Zhang D, Xu C, Marelli B, Qi J, Yu H, Qin G, Sircar A, Radvanyi L, Lo K-M. Preclinical evaluation of M7824 (MSB0011359C), a novel bifunctional fusion protein targeting the PD-L1 and TGFβ pathways. Keystone Symposia: TGFβ in Immunity, Inflammation and Cancer, January 2017, Taos, NM.
  • Lan Y, Zhang D, Xu C, Marelli B, Qi J, Yu H, Qin G, Xu X, Wang H, Sircar A, Brunkhorst B, Austin E, Radvanyi L, Lo K-M. Preclinical Evaluation and Mechanistic Characterization of M7824 (MSB0011359C), a Novel Bifunctional Fusion Protein Targeting the PD-L1 and TGF-β Pathways. AACR Annual Meeting 2017, Washington DC.
  • Xu C, Marelli B, Qi J, Qin G, Yu H, Jenkins M, Lo K-M., Halle J, Lan Y. Combination therapy with M7824 (MSB0011359C) and NHS-muIL12 enhances antitumor efficacy in preclinical cancer models. SITC, Nov 2018, Washington DC.
  • Lan Y, Zaynagetdinov R, Hance K, Chu C, Xu C, Marelli B, Qi J, Qin G, Yu H, Kradjian G, Zhang Y, Jenkins M, Halle J, Lo K-M. M7824 (MSB0011359C) is an effective combination partner with standard-of-care therapies in tumor models. SITC, Nov 2018, Washington DC.
  • Lan Y, Xu C, Yu H, Qin G, Marelli B, Qi J, Fontana R, Deshpande A, Locke G, Rolfe A, Jenkins M, Halle J, Lo K-M. Combination of M7824 (MSB0011359C) and radiation therapy enhances antitumor activity, increases immune response, and modulates radiation-induced fibrosis in cancer models. ImmunoRAD, Sept 2018, Villejuif, France.

Redirect

You have accessed https://www.emdgroup.com, but for users from your part of the world, we originally designed the following web presence https://www.merckgroup.com.

Let's go

Share Disclaimer

By sharing this content, you are consenting to share your data to this social media provider. More information are available in our Privacy Statement